Press Releases

Oasmia intends to issue notice to an extraordinary general meeting at the request of a shareholder and announces that it is subject to legal proceedings with a major shareholder concerning the company’s warrants 2018/2019

Oasmia Pharmaceutical AB (publ) (“Oasmia”) hereby announces that Oasmia’s largest shareholder, Arwidsro Investment AB and Per Arwidson (together “Arwidsro”), on the basis of Chapter 7 Sectio...

Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union

Apealea is approved in the European Union for treatment of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer in combination with carboplatin in first re...

New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted

Oasmia Pharmaceutical AB (Nasdaq: OASM) announces that the United States Patent and Trademark Office (USPTO) has issued a notification of allowance of a patent for its unique nanotech method to produc...

Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the total amount of SEK 80,000,000 with...

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 29 November 2017, on 18 April 2018 and on 7 September 2018, issued convertible loans with total nominal amount of MSEK...

Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma

Overall response rate data from the (RXE) Phase II study conducted in the US and Sweden met its primary end points and treatment with Doxophos Vet was generally well tolerated. Oasmia’s assessmen...

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 18 April 2018 issued a convertible loan with a total nominal amount of MSEK 26. In total MSEK 14 of the convertible lo...

Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2018

Oasmia Pharmaceutical AB (publ) held its annual general meeting on Tuesday 25 September 2018. The following main resolutions were passed at the meeting. Adoption of balance sheets and profi...

Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union

Apealea receives positive CHMP opinion in the European Union for treatment of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer in combination with carb...

Update regarding the Market Authorization Application of Apealea in the European Union

With reference to yesterday’s communicated agenda for this week’s meeting by the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency (EMA) has informed Oasmia Phar...